title: Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis.
abstract: A patient with rheumatoid arthritis developed a reversible, primary cutaneous, large B cell lymphoma during prolonged methotrexate (MTX) treatment. Regression of the skin lesions after discontinuation of the drug suggested a close relationship to MTX. Increased clinical awareness, discontinuation of MTX, and close observation are important in the initial management of this rare lymphoproliferative disorder.
authors.affiliation: Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada. kathy.carey@swchsc.on.ca
authors.forename: A G
authors.initials: AG
authors.lastname: Fam
authors.forename: B
authors.initials: B
authors.lastname: Perez-Ordonez
authors.forename: K
authors.initials: K
authors.lastname: Imrie
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000139:chemically induced* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000473:pathology; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate